The Prospects for Cisplatin and Nab-Paclitaxel Combination Therapy in Patients With Pre-Treated Triple-Negative Breast Cancer. Description of the Clinical Case.

Medical Council
doi 10.21518/2079-701x-2018-10-49-55
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Remedium, Ltd.

Related search

Nab-Paclitaxel for the Management of Triple-Negative Metastatic Breast Cancer

Anti-Cancer Drugs
Cancer ResearchOncologyPharmacology
2015English

Cisplatin Versus Carboplatin in Combination With Paclitaxel as Neoadjuvant Regimen for Triple Negative Breast Cancer

OncoTargets and Therapy
OncologyPharmacology
2017English

Cisplatin in Combination With Zoledronic Acid: A Synergistic Effect in Triple-Negative Breast Cancer Cell Lines

International Journal of Oncology
Cancer ResearchOncology
2013English

The Results of a Study of Chemotherapy With Bevacizumab, Oxaliplatin and Paclitaxel in Patients With Metastatic Triple Negative Breast Cancer

Malignant tumours
2017English

Impact of Radiation Therapy on Survival in Patients With Triple‑negative Breast Cancer

Oncology Letters
Cancer ResearchOncology
2013English

Nab-Paclitaxel Monotherapy in Patients With Metastatic Breast Cancer With Visceral Crisis: Evaluation of Efficacy and Tolerability in Clinical Practice

Medical Council
2019English

The Clinical Promise of Immunotherapy in Triple-Negative Breast Cancer

Cancer Management and Research
Oncology
2018English

MiR-34b Is Associated With Clinical Outcome in Triple-Negative Breast Cancer Patients

Diagnostic Pathology
Forensic MedicineMedicinePathologyHistology
2012English

Severe and Prolonged Lymphopenia Observed in Patients Treated With Bendamustine and Erlotinib for Metastatic Triple Negative Breast Cancer

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy